Efferon LPS Hemoadsorption in in Patients With Thermal Burns
NCT: NCT07568132 · NOT_YET_RECRUITING
Brief Summary
The aim of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoadsorption using the Efferon® LPS device to reduce the severity of clinical symptoms and to prevent the progression of multiple organ dysfunction or to arrest its development in patients with burn disease with an RFI score ≥71 and ≤181. Patients will be randomized in two groups: control group receiving baseline therapy (including CRRT) and treatment group receiving baseline therapy and Efferon® LPS hemoadsorption in combination with CRRT.
Frequently Asked Questions
What is Efferon LPS Hemoadsorption in in Patients With Thermal Burns?
Efferon LPS Hemoadsorption in in Patients With Thermal Burns is a clinical trial registered under NCT07568132. Current status: NOT_YET_RECRUITING.
What is the status of NCT07568132?
The current status of NCT07568132 (Efferon LPS Hemoadsorption in in Patients With Thermal Burns) is: NOT_YET_RECRUITING.
When did Efferon LPS Hemoadsorption in in Patients With Thermal Burns start?
Efferon LPS Hemoadsorption in in Patients With Thermal Burns started on 2026-05-15.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.